Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access ...

Sputum is considered a noninvasive marker of airway inflammation, and its color is an indicator of bronchiectasis disease ...

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower ...

Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.

Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.

Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease ...

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what ...

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured ...

Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in ...

Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.